$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041294 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$65.00K	$46.00K	$21.00K
YoY Change	16.07%	119.05%	-36.36%
Cost Of Revenue	$12.00K	$30.00K	$0.00
YoY Change			-100.0%
Gross Profit	$53.00K	$16.00K	$21.00K
YoY Change	-5.36%	-23.81%	-116.94%
Gross Profit Margin	81.54%	34.78%	100.0%
Selling, General & Admin	$10.86M	$5.439M	$5.170M
YoY Change	209.76%	5.2%	187.38%
% of Gross Profit	20484.91%	33993.75%	24619.05%
Research & Development	$3.200M	$2.734M	$1.372M
YoY Change	51.87%	99.27%	-31.61%
% of Gross Profit	6037.74%	17087.5%	6533.33%
Depreciation & Amortization	$58.00K	$53.00K	$28.00K
YoY Change	-65.88%	89.29%	-84.09%
% of Gross Profit	109.43%	331.25%	133.33%
Operating Expenses	$14.06M	$2.734M	$1.372M
YoY Change	150.48%	99.27%	-63.94%
Operating Profit	-$14.00M	-$8.157M	-$6.521M
YoY Change	152.05%	25.09%	65.97%
Interest Expense	$659.0K	-$16.00K
YoY Change	55.79%
% of Operating Profit
Other Income/Expense, Net		$294.0K	$172.0K
YoY Change		70.93%	237.25%
Pretax Income	-$12.58M	-$7.816M	-$6.385M
YoY Change	186.53%	22.41%	66.88%
Income Tax
% Of Pretax Income
Net Earnings	-$12.58M	-$7.816M	-$6.385M
YoY Change	186.53%	22.41%	66.88%
Net Earnings / Revenue	-19347.69%	-16991.3%	-30404.76%
Basic Earnings Per Share		-$0.16	-$0.13
Diluted Earnings Per Share	-$0.26	-$0.16	-$132.8K
COMMON SHARES
Basic Shares Outstanding	48.84M shares	48.67M shares	48.05M shares
Diluted Shares Outstanding		48.64M shares	48.08M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.07M	$22.43M	$36.75M
YoY Change	-61.77%	-38.95%	-2.91%
Cash & Equivalents	$5.439M	$15.26M	$29.76M
Short-Term Investments	$7.631M	$7.167M	$6.986M
Other Short-Term Assets	$302.0K	$263.0K	$4.405M
YoY Change	-33.63%	-94.03%	2636.02%
Inventory
Prepaid Expenses
Receivables	$1.184M	$48.00K	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$14.56M	$22.74M	$41.15M
YoY Change	-59.92%	-44.73%	8.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$824.0K	$136.0K	$118.0K
YoY Change	322.56%	15.25%	-98.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.688M	$2.102M	$2.138M
YoY Change	40.43%	-1.68%	71.18%
Total Long-Term Assets	$4.825M	$5.119M	$5.135M
YoY Change	15.79%	-0.31%	-79.5%
TOTAL ASSETS
Total Short-Term Assets	$14.56M	$22.74M	$41.15M
Total Long-Term Assets	$4.825M	$5.119M	$5.135M
Total Assets	$19.38M	$27.86M	$46.29M
YoY Change	-52.13%	-39.81%	-26.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.443M	$2.788M	$957.0K
YoY Change	1609.02%	191.33%	159.35%
Accrued Expenses	$2.209M	$1.721M	$1.767M
YoY Change	174.07%	-2.6%	343.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.652M	$4.716M	$2.895M
YoY Change	535.71%	62.9%	277.44%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$495.0K	$543.0K	$695.0K
YoY Change	-24.89%	-21.87%	161.28%
Total Long-Term Liabilities	$495.0K	$543.0K	$695.0K
YoY Change	-24.89%	-21.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.652M	$4.716M	$2.895M
Total Long-Term Liabilities	$495.0K	$543.0K	$695.0K
Total Liabilities	$9.147M	$5.259M	$3.590M
YoY Change	352.82%	46.49%	247.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$409.5M	-$396.9M	-$376.2M
YoY Change	7.61%	5.52%
Common Stock	$49.00K	$48.00K	$48.00K
YoY Change	2.08%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.23M	$22.60M	$42.70M
YoY Change
Total Liabilities & Shareholders Equity	$19.38M	$27.86M	$46.29M
YoY Change	-52.13%	-39.81%	-26.62%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$12.58M	-$7.816M	-$6.385M
YoY Change	186.53%	22.41%	66.88%
Depreciation, Depletion And Amortization	$58.00K	$53.00K	$28.00K
YoY Change	-65.88%	89.29%	-84.09%
Cash From Operating Activities	-$9.758M	-$5.671M	-$4.968M
YoY Change	60.78%	14.15%	43.71%
INVESTING ACTIVITIES
Capital Expenditures	$198.0K	$184.0K	-$20.00K
YoY Change	13.14%	-1020.0%	-77.01%
Acquisitions
YoY Change
Other Investing Activities	-$16.00K	-$152.0K	$270.0K
YoY Change	-100.45%	-156.3%	-196.77%
Cash From Investing Activities	-$214.0K	-$336.0K	$250.0K
YoY Change	-106.36%	-234.4%	-168.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	147.0K	233.0K	25.00K
YoY Change		832.0%	-16.67%
NET CHANGE
Cash From Operating Activities	-9.758M	-5.671M	-4.968M
Cash From Investing Activities	-214.0K	-336.0K	250.0K
Cash From Financing Activities	147.0K	233.0K	25.00K
Net Change In Cash	-9.825M	-5.774M	-4.693M
YoY Change	263.08%	23.03%	23.73%
FREE CASH FLOW
Cash From Operating Activities	-$9.758M	-$5.671M	-$4.968M
Capital Expenditures	$198.0K	$184.0K	-$20.00K
Free Cash Flow	-$9.956M	-$5.855M	-$4.948M
YoY Change	59.45%	18.33%	46.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Central Index Key EntityCentralIndexKey	0000946644
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Manufacturing Costs ManufacturingCosts		usd
	us-gaap	Manufacturing Costs ManufacturingCosts		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q3	AIM	Cashless Warrant Conversion CashlessWarrantConversion		usd
	AIM	Cashless Warrant Conversion CashlessWarrantConversion		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	AIM	Abandonment Of Patent And Trademark Rights AbandonmentOfPatentAndTrademarkRights		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Entity File Number EntityFileNumber	001-27072
	dei	Entity Registrant Name EntityRegistrantName	AIM IMMUNOTECH INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-0845822
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2117 SW Highway 484
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ocala
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34473
	dei	City Area Code CityAreaCode	(352)
	dei	Local Phone Number LocalPhoneNumber	448-7797
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AIM
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48841656	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15264000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27053000	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7167000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7137000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1676000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	455000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	22742000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	36321000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	136000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	195000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	727000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	829000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2154000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1941000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2102000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1202000	usd
CY2023Q3	us-gaap	Assets Assets	27861000	usd
CY2022Q4	us-gaap	Assets Assets	40488000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2788000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	377000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1721000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	806000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	207000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	178000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4716000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1361000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	543000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	659000	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48797450	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48797450	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	133333	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	561104	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	418796000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	418270000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396932000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-380546000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	22602000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27861000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40488000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	137000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	85000	usd
CY2023Q3	us-gaap	Revenues Revenues	46000	usd
CY2022Q3	us-gaap	Revenues Revenues	21000	usd
	us-gaap	Revenues Revenues	137000	usd
	us-gaap	Revenues Revenues	85000	usd
CY2023Q3	us-gaap	Manufacturing Costs ManufacturingCosts	30000	usd
	us-gaap	Manufacturing Costs ManufacturingCosts	30000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2734000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1372000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7739000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4883000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5439000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5170000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10280000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9569000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	8203000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	6542000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	18049000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	14452000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8157000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6521000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17912000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14367000	usd
CY2023Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-310000	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-365000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-201000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1769000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	294000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	172000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	811000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	296000	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	39000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	16000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-35000	usd
CY2023Q3	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-318000	usd
CY2022Q3	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-328000	usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-900000	usd
	AIM	Gain From Sale Of Income Tax Operating Loss GainFromSaleOfIncomeTaxOperatingLoss	-749000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-7816000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-6385000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16386000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15056000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2023Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48635165	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48635165	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48079210	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48079210	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48483802	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48483802	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	48036559	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48036559	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30135000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	233000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7816000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	22602000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	48780000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	275000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6385000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	42695000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38468000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	338000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	182000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16386000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	22602000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	56879000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	80000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	792000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15056000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	42695000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16386000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-15056000	usd
	us-gaap	Depreciation Depreciation	30000	usd
	us-gaap	Depreciation Depreciation	29000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-35000	usd
	AIM	Abandonment Of Patent And Trademark Rights AbandonmentOfPatentAndTrademarkRights	14000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	150000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	57000	usd
	AIM	Noncash Lease Expense NoncashLeaseExpense	151000	usd
	AIM	Noncash Lease Expense NoncashLeaseExpense	-717000	usd
	AIM	Loss Gain From Sale Of Income Tax Operating Losses LossGainFromSaleOfIncomeTaxOperatingLosses	900000	usd
	AIM	Loss Gain From Sale Of Income Tax Operating Losses LossGainFromSaleOfIncomeTaxOperatingLosses	749000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	182000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	792000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-201000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1768000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	9000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1676000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1641000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-192000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	500000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-136000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	717000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	73000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2411000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	758000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	915000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1329000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11509000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10039000	usd
	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	924000	usd
	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	9082000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1155000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1661000	usd
	AIM	Proceeds From Payments To Purchase Of Property And Equipment ProceedsFromPaymentsToPurchaseOfPropertyAndEquipment	-10000	usd
	AIM	Proceeds From Payments To Purchase Of Property And Equipment ProceedsFromPaymentsToPurchaseOfPropertyAndEquipment	300000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	377000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	96000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-618000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7625000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	338000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	80000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	338000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11789000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2334000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27053000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32093000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15264000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29759000	usd
	AIM	Operating Lease Liability Arising From Obtaining Right Of Use Asset OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset	49000	usd
	AIM	Operating Lease Liability Arising From Obtaining Right Of Use Asset OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset	717000	usd
	AIM	Unrealized Gain Loss On Marketable Investments UnrealizedGainLossOnMarketableInvestments	-71000	usd
	AIM	Unrealized Gain Loss On Marketable Investments UnrealizedGainLossOnMarketableInvestments	-1170000	usd
	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	6000	usd
	AIM	Conversion Of Series B Preferred ConversionOfSeriesBPreferred	2000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	300000	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	182000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	792000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	35000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	179000	usd
CY2023Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7167000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	7137000	usd
CY2023Q3	us-gaap	Marketable Securities MarketableSecurities	7167000	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	7167000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-309000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-42000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-267000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-201000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-130000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-71000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	7137000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	7137000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-365000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-15000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-350000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1768000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-598000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1170000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	29000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1459000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	492000	usd
CY2023Q3	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	127000	usd
CY2022Q4	AIM	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	110000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	106000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	203000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1721000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	806000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1555000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2233000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1419000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2038000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	136000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	195000	usd
	us-gaap	Depreciation Depreciation	30000	usd
	us-gaap	Depreciation Depreciation	29000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1941000	usd
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	377000	usd
	AIM	Finitelived Intangible Assets Abandonments FinitelivedIntangibleAssetsAbandonments	14000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	150000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2154000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	58000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	225000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	217000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	215000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	194000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1245000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2154000	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.20
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q3	AIM	Common Stock Shares With Limitations And Restrictions On Usage CommonStockSharesWithLimitationsAndRestrictionsOnUsage	8000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48797450	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48797450	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48084287	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48084287	shares
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	264000	usd
CY2020Q1	AIM	Warrant Modifications WarrantModifications	46000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15000	shares
CY2023Q2	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.030	pure
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	327055	shares
	AIM	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	209000	usd
CY2023Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.030	pure
CY2023Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	6271	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	14110000	usd
CY2023Q3	us-gaap	Derivative Assets DerivativeAssets	7167000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	25180000	usd
CY2022Q4	us-gaap	Derivative Assets DerivativeAssets	7137000	usd
	AIM	Percentage Of Probability PercentageOfProbability	0.050	pure
	AIM	Floor Rate Used As Proxy For Future Volatility Percentage FloorRateUsedAsProxyForFutureVolatilityPercentage	1	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P43M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P42M
	AIM	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.10	pure
CY2022	AIM	Percentage Of Incremental Borrowing Rate PercentageOfIncrementalBorrowingRate	0.10	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	73000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	264000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	221000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	200000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	133000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	141000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	750000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	727000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	829000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	750000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	837000	usd
	us-gaap	Payments For Rent PaymentsForRent	230000	usd
	us-gaap	Payments For Rent PaymentsForRent	75000	usd
	us-gaap	Short Term Lease Payments ShortTermLeasePayments	198000	usd
	us-gaap	Short Term Lease Payments ShortTermLeasePayments	8000	usd

Files In Submission

Name	View Source	Status
aim-20230930_cal.xml	Edgar Link	unprocessable
aim-20230930_pre.xml	Edgar Link	unprocessable
0001493152-23-041294-index-headers.html	Edgar Link	pending
0001493152-23-041294-index.html	Edgar Link	pending
0001493152-23-041294.txt	Edgar Link	pending
0001493152-23-041294-xbrl.zip	Edgar Link	pending
aim-20230930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
aim-20230930_lab.xml	Edgar Link	unprocessable
aim-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2023 Q4 Form 10-Q Financial Statement

#000149315223041294 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2023 Q4 Form 10-Q Financial Statement

#000149315223041294 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim